ANIP · CIK 0001023024 · operating
ANI Pharmaceuticals develops, manufactures, and markets branded and generic pharmaceutical products across multiple dosage forms and therapeutic areas. The company's portfolio encompasses injectables, softgel capsules, oral solid dose products, semi-solids, liquids, and topicals, alongside controlled substances and potent active pharmaceutical ingredients. The company also commercializes specialty products including Cortrophin gel, ILUVIEN (an intraocular implant for diabetic macular edema), and YUTIQ (an intraocular implant for uveitis).
The company operates across both generic and branded pharmaceutical segments, with distribution channels spanning wholesalers, retail pharmacy chains, specialty pharmacies, group purchasing organizations, hospitals, clinics, and physician offices. ANI Pharmaceuticals serves both domestic and international markets, though the United States represents its primary market focus.
Based in Baudette, Minnesota, the company operates with approximately 897 full-time employees and maintains manufacturing and distribution capabilities across multiple facilities. ANI Pharmaceuticals was incorporated in Delaware in 2001 and is listed on the Nasdaq exchange.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $3.32 | $3.50 | +419.2% | |
| 2024 | $-1.04 | $-1.04 | -222.4% | |
| 2023 | $0.85 | $0.86 | +127.9% | |
| 2022 | $-3.05 | $-3.05 | +10.3% | |
| 2021 | $-3.40 | $-3.40 | -1033.3% | |
| 2020 | $-0.30 | $-0.30 | +26.8% | |
| 2019 | $-0.41 | $-0.41 | -189.1% | |
| 2018 | $0.46 | $0.46 | +155.4% | |
| 2017 | $-0.83 | $-0.83 | -822.2% | |
| 2016 | $-0.09 | $-0.09 | -136.0% | |
| 2015 | $0.25 | $0.25 | -90.3% | |
| 2014 | $2.59 | $2.61 | — | |
| 2013 | — | — | — | |
| 2012 | $-1.27 | $-1.27 | -144.2% | |
| 2011 | $-0.52 | $-0.52 | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-27 | 0001023024-26-000014 | SEC ↗ |
| 2024-12-31 | 2025-02-28 | 0001023024-25-000015 | SEC ↗ |
| 2023-12-31 | 2024-02-29 | 0001023024-24-000026 | SEC ↗ |
| 2022-12-31 | 2023-03-09 | 0001023024-23-000005 | SEC ↗ |
| 2021-12-31 | 2022-03-15 | 0001023024-22-000004 | SEC ↗ |
| 2020-12-31 | 2021-03-11 | 0001023024-21-000007 | SEC ↗ |
| 2019-12-31 | 2020-02-27 | 0001104659-20-025744 | SEC ↗ |
| 2018-12-31 | 2019-02-27 | 0001144204-19-010541 | SEC ↗ |
| 2017-12-31 | 2018-02-27 | 0001144204-18-011197 | SEC ↗ |
| 2016-12-31 | 2017-03-02 | 0001144204-17-012507 | SEC ↗ |
| 2015-12-31 | 2016-02-23 | 0001144204-16-083848 | SEC ↗ |
| 2014-12-31 | 2015-02-23 | 0001144204-15-011270 | SEC ↗ |
| 2013-12-31 | 2014-02-28 | 0001144204-14-012277 | SEC ↗ |